Dr. Anna Berkenblit, M.D., M.M.S., brings to Surrozen’s board more than 15 years of experience in clinical development, particularly of novel anticancer therapies in the life science industry.
Dr. Anna Berkenblit, M.D., M.M.S., brings to Surrozen’s board more than 15 years of experience in clinical development, particularly of novel anticancer therapies in the life science industry.
Dr. Anna Berkenblit, M.D., M.M.S., brings to Surrozen’s board more than 15 years of experience in clinical development, particularly of novel anticancer therapies in the life science industry.